Skip to main content

One Oncologist’s Firsthand Experience with Serious Illness: What Your Patients Want

Web Exclusives - Practice Management
Meg Barbor, MPH

There’s really only one way to identify how patients are coping with serious illness: by asking them, according to Thomas J. Smith, MD, FACP, Director of Palliative Medicine, Johns Hopkins Medical Institutions, Baltimore, MD.

At the 2018 ASCO Quality Care Symposium, Dr Smith spokeabout his own brushes with several serious illnesses, including aortic aneurysm and a diagnosis of prostate cancer. “I want to help you identify how patients like me are coping with illnesses, by asking about our prior experience,” Dr Smith said.

Dos and Don’ts

“The take-home message is, the diagnosis of any serious illness is ‘an existential slap,’ to quote Nessa Coyle, a specialist in end-of-life care at Memorial Sloan Kettering. Your patient, like me, may not be able to focus on much for a while. Some recognition that this can be upsetting is really welcomed,” he advised.

Don’t assume that your patient understands the big picture about survival, treatment options, and treatment toxicities, he said. Don’t give bad news over the phone, unless there is no other alternative, and always ask if patients want to discuss what their diagnosis means in terms of their prognosis.

What Patients Want

According to Dr Smith, most patients really want answers to the following key questions:

  • Is this curable? “We lay awake thinking about these things anyway, so it’s not as if you’re breaking new ground for us,” Dr Smith said
  • If it’s not curable, what can be done about it? Patients want to be provided with actual numbers
  • Finally, what will the treatments do to me?

Ask during treatments—and at each visit—how the patient is coping, and ask the same question of the patient’s family. “You might be surprised at what you hear,” he said.

Recognize that some encouragement from the patient’s oncologist goes a long way for patients. “Saying something like, ‘Hey, you’re really hanging in there. You should be proud of yourself,’ can make a huge impact,” Dr Smith recalled. “I’ve heard that from 2 of my doctors, and it was very important to me at difficult times.” Hearing from someone who has had a similar experience can also help immensely, but when in doubt, remember that a hug goes a long way.

Fear and Depression

After finding out that his prostate-specific antigen level was rising, Dr Smith was overcome with concerns of debility and death from his prostate cancer. He began radiation and androgen-deprivation therapy (ADT), and within 2 weeks he was experiencing behavioral changes, mood swings, fatigue, muscle and strength loss, sleeplessness, and incessant hot flashes and sweating. Dr Smith remembers dripping on patients during procedures. This, he found, was when he was most in need of encouragement.

For patients diagnosed with a serious illness such as cancer, remember that medications and talk therapy really do work, he said. Ask the patient what he or she is most afraid of, and keep in mind that expert information, tailored to what the patient most fears, really helps.

Dr Smith had sexual side effects and muscle loss as a result of restrictive lung disease, and he lost 50% of his arm and leg strength, despite daily workouts.

Because of his use of ADT, Dr Smith also suffered a ministroke, and when he began taking duloxetine (Cymbalta) for ADT-associated hot flashes, he became depressed and suicidal. He couldn’t exercise or run (his lifelong passion), and he was eventually hospitalized for a week to prevent him from committing suicide. He then found a study that cited a 41% increase in depression among individuals receiving duloxeine. “I wish somebody had told me that,” he emphasized.

When he stopped taking the drug, all the suicidal notions went away, and his mood was stabilized with mirtazapine. Dr Smith’s message for patients with a serious illness is, “If you take nothing else away from what I’m saying, take this: do not kill yourself. Your family will never be the same.”

Financial Toxicity

In addition to physical side effects, he suffered significant financial toxicity. He also turned in grant money, because he had no energy to finish his research projects, he was extremely anxious about keeping his job and health insurance, and the mere thought of starting another program sapped his energy.

Address this financial toxicity, he advised. “Remember that no one will bring up work or money issues unless you do,” Dr Smith said.

“Finally, just be prepared to listen. That’s probably the biggest skill that I’ve admired in my medical care team,” Dr Smith concluded.

Related Items
Artificial Intelligence and the Future of Healthcare
Fop Johnson
Web Exclusives in Practice Management
Artificial intelligence tools and applications have shown great promise in delivering higher quality healthcare, but current offerings are at various stages of maturity and capability and are not yet in widespread use.
CMOM-HEM/ONC Course: A Valuable Resource for Practice Managers
Ina Huang
Web Exclusives in Practice Management
In the evolving landscape of today’s healthcare industry, more and more demands are being placed on practice managers and their staff.
The Flaw in Infusion Scheduling
Web Exclusives in Practice Management
In reality, scheduling appointments with significant lead times, often weeks or months before the actual appointment, may actually cause more problems and serve fewer patients.
Applying Business Principles to Everyday Practice
Meg Barbor, MPH
Web Exclusives in Practice Management
Given the high cost of oncology drugs, it is important for pharmacists to become more business savvy regarding their practices.
Identifying the Problem Is Key to Quality Improvement in Cancer Care
Meg Barbor, MPH
Web Exclusives in Practice Management
“There are a number of ways to go wrong when you’re trying to improve something,” said Kaveh G. Shojania, MD, Director, Centre for Quality Improvement and Patient Safety, University of Toronto, Canada, and Editor-in-Chief, BMJ Quality & Safety, who delivered the keynote address at the 2018 ASCO Quality Care Symposium.
FDA Perspective: Reducing Cost, Increasing Access to Cancer Care
Chase Doyle
Web Exclusives in Practice Management
In a time when the country feels more politically divided than ever, there is broad consensus that Medicare should be allowed to negotiate prescription drug prices directly with drug makers, and that the FDA should expedite approvals of generic cancer drugs to lower patients’ out-of-pocket costs.
Harnessing the Power of Data Collection and Coordination in Oncology Practice
Meg Barbor, MPH
Web Exclusives in Practice Management
Business intelligence is the process of collecting data from disparate systems—internal and external—and turning it into information that is meaningful and actionable toward achieving strategic goals.
MIPS: How to Be Successful Today and in the Future
Toni Gress
Web Exclusives in Practice Management
The McKesson value-based care team employs a combination of tactics to help practices in The US Oncology Network achieve success in the Merit-Based Incentive Payment System (MIPS). One of the challenges with the new MIPS program is the need to focus on the current year’s performance, while taking steps to ensure that practices are successful in future years.
Oncology Practice Landscape in 2018: ASCO Survey Shows Interactions with Payers Top Concern
Eileen Koutnik-Fotopoulos
Web Exclusives in Practice Management
Oncology practices are challenged by day-to-day operational functions, which are often related to payment, reimbursement, and competition, according to the new survey titled “The State of Oncology Practice in America” from the American Society of Clinical Oncology (ASCO) on the oncology practice landscape in the United States.
FDA Commissioner Outlines New Plan to Increase Biosimilars by “Balancing Innovation and Competition”
Eileen Koutnik-Fotopoulos
Web Exclusives in Practice Management
FDA Commissioner Scott Gottlieb, MD, has been outspoken about the critical need to reign in drug prices. Biosimilars are crucial for improving patient access to biologic drugs at an affordable cost. Biologics are now key in the treatment of cancer and autoimmune conditions. But cost remains an obstacle to access to drug therapy.
Last modified: June 11, 2020